Anaplastic Large Cell Lymphoma Clinical Trials

17 recruitingLast updated: June 18, 2026

There are 17 actively recruiting anaplastic large cell lymphoma clinical trials across 8 countries. Studies span Phase 1, Phase 2, Phase 3. Top locations include Rochester, Minnesota, United States, New York, New York, United States, Columbus, Ohio, United States. Updated daily from ClinicalTrials.gov.


Anaplastic Large Cell Lymphoma Trials at a Glance

17 actively recruiting trials for anaplastic large cell lymphoma are listed on ClinicalTrialsFinder across 6 cities in 8 countries. The largest study group is Phase 1 with 9 trials, with the heaviest enrollment activity in Rochester, New York, and Columbus. Lead sponsors running anaplastic large cell lymphoma studies include Mayo Clinic, Memorial Sloan Kettering Cancer Center, and National Cancer Institute (NCI).

Browse anaplastic large cell lymphoma trials by phase

Treatments under study

About Anaplastic Large Cell Lymphoma Clinical Trials

Looking for clinical trials for Anaplastic Large Cell Lymphoma? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Anaplastic Large Cell Lymphoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Anaplastic Large Cell Lymphoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 117 of 17 trials

Recruiting
Phase 1

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Myelodysplastic SyndromeB-cell Non Hodgkin LymphomaRefractory Acute Myeloid Leukemia+16 more
Mayo Clinic99 enrolled2 locationsNCT03017820
Recruiting
Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedPeripheral T Cell LymphomaRelapsed Peripheral T-Cell Lymphoma+4 more
Mayo Clinic21 enrolled2 locationsNCT06508463
Recruiting
Phase 2

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaHodgkin Lymphoma+16 more
Fred Hutchinson Cancer Center60 enrolled1 locationNCT04195633
Recruiting
Phase 1

A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Anaplastic Large Cell LymphomaAnaplastic Lymphoma Kinase
Memorial Sloan Kettering Cancer Center30 enrolled7 locationsNCT07001384
Recruiting
Phase 1

A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)

Peripheral T Cell LymphomaAnaplastic Large Cell LymphomaMycosis Fungoides+7 more
National Cancer Institute (NCI)60 enrolled1 locationNCT07055477
Recruiting
Phase 2

Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL

Anaplastic Large Cell Lymphoma, ALK-Positive
New York Medical College20 enrolled1 locationNCT07013565
Recruiting

A Registry for People With T-cell Lymphoma

T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+27 more
Memorial Sloan Kettering Cancer Center1,000 enrolled26 locationsNCT05978141
Recruiting
Phase 3

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy

Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAnaplastic Large Cell Lymphoma, ALK-negativeFollicular Helper T-Cell Lymphoma+1 more
Eastern Cooperative Oncology Group294 enrolled158 locationsNCT06724237
Recruiting
Phase 1

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Hodgkin LymphomaNon-Hodgkin LymphomaPeripheral T Cell Lymphoma+4 more
Baylor College of Medicine90 enrolled2 locationsNCT06176690
Recruiting
Phase 3

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Lymphoma, T-CellPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc.150 enrolled34 locationsNCT06561048
Recruiting
Phase 1

Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

LymphomaLeukemiaHodgkin Disease+4 more
Medical College of Wisconsin42 enrolled1 locationNCT05544968
Recruiting
Phase 1

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

T-cell LymphomaAnaplastic Large Cell LymphomaAdult T-cell Leukemia/Lymphoma+3 more
National Cancer Institute (NCI)20 enrolled1 locationNCT07388563
Recruiting

Breast Implant-associated Anaplastic Large Cell Lymphoma (BIA-ALCL) Registry

Anaplastic Large Cell Lymphoma Associated With Breast Implants (BIA-ALCL)
The Lymphoma Academic Research Organisation150 enrolled31 locationsNCT04220970
Recruiting
Phase 1Phase 2

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Princess Maxima Center for Pediatric Oncology65 enrolled2 locationsNCT04925609
Recruiting
Phase 2Phase 3

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

CancerRenal Cell CarcinomaLymphoma+8 more
Cancer Research UK30 enrolled27 locationsNCT05770037
Recruiting

Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

Multiple Endocrine Neoplasia Type 1Multiple Endocrine Neoplasia Type 2Rare Disorders+337 more
Sanford Health20,000 enrolled2 locationsNCT01793168
Recruiting
Phase 1

A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma

Hodgkin's LymphomaAnaplastic Large Cell Lymphoma
Ruijin Hospital32 enrolled1 locationNCT06494371